Kono Michihide, Satomi Takafumi, Abukawa Harutsugi, Hasegawa On, Watanabe Masato, Chikazu Daichi
Instructor, Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Tokyo, Japan.
Associate Professor, Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Tokyo, Japan.
J Oral Maxillofac Surg. 2017 Feb;75(2):336-342. doi: 10.1016/j.joms.2016.08.013. Epub 2016 Aug 24.
A ranula is a pseudocyst caused by mucous extravasation from the sublingual gland. Recently, a sclerosing agent, OK-432 (picibanil), has been reported to be highly effective for treating lymphangioma and cervical cystic lesions. The present study assessed the effectiveness of OK-432 injection therapy for intraoral ranula to clarify whether it can be used as the primary treatment.
The present study was a retrospective clinical study of patients with intraoral ranula who received OK-432 injection therapy from 2005 to 2015. The ranula size was measured on computed tomography or magnetic resonance imaging studies. We dissolved 1 Klinische Einheit (KE) unit of OK-432 powder in normal saline equal to the aspiration volume. The primary endpoint was the treatment results. The secondary endpoints were the relation between the treatment results and the lesion length and aspiration volume.
A total of 23 patients received OK-432 injection therapy for an intraoral ranula. The mean lesion size was 19.96 mm. The mean aspiration volume was 2.14 mL. The number of injections was 1 to 4 (mean 1.70). The treatment results were complete regression (CR) in 18 (78.2%), partial regression (PR) in 3 (13.0%), and no response (NR) in 2 (8%) patients after the last injection. The overall efficacy rate was 91.2% (21 of 23). No serious complications were observed. The lesion length and aspiration volume of the CR group was 17.38 mm and 1.40 mL, respectively. The lesion length and aspiration volume of the PR/NR group was 29.20 mm and 4.80 mL, respectively. The PR/NR group lesions were significantly larger than the CR group lesions.
OK-432 injection therapy for intraoral ranula is safe and effective compared with other surgical therapies. This therapy could potentially become a primary treatment of intraoral ranula.
舌下腺黏液外渗所致的黏液囊肿是一种假性囊肿。最近，有报道称硬化剂OK-432（匹鲁卡品）在治疗淋巴管瘤和颈部囊性病变方面疗效显著。本研究评估OK-432注射疗法治疗口腔内黏液囊肿的有效性，以明确其是否可作为主要治疗方法。
本研究是一项对2005年至2015年接受OK-432注射疗法的口腔内黏液囊肿患者的回顾性临床研究。通过计算机断层扫描或磁共振成像测量黏液囊肿大小。我们将1个临床单位（KE）的OK-432粉末溶解于与抽出液体积相等的生理盐水中。主要终点是治疗结果。次要终点是治疗结果与病变长度和抽出液体积之间的关系。
共有23例患者接受了OK-432注射疗法治疗口腔内黏液囊肿。平均病变大小为19.96毫米。平均抽出液体积为2.14毫升。注射次数为1至4次（平均1.70次）。末次注射后，治疗结果为完全消退（CR）的有18例（78.2%），部分消退（PR）的有3例（13.0%），无反应（NR）的有2例（8%）。总有效率为91.2%（23例中的21例）。未观察到严重并发症。CR组的病变长度和抽出液体积分别为17.38毫米和1.40毫升。PR/NR组的病变长度和抽出液体积分别为29.20毫米和4.80毫升。PR/NR组的病变明显大于CR组的病变。
与其他手术治疗方法相比，OK-432注射疗法治疗口腔内黏液囊肿安全有效。该疗法有可能成为口腔内黏液囊肿的主要治疗方法。
